KALA YTD Return
Start date: 12/31/2019
End date: 06/01/2020
Start price/share: $3.69
End price/share: $13.40
Dividends collected/share: $0.00
KALA YTD return: 263.14%
Annualized Gain: 631.89%
Starting investment: $10,000.00
Ending investment: $36,314.00
Years: 0.42


KALA YTD return is presented with the assumption of reinvestments of any dividends on ex-date.
Use our YTD Return Calculator to compare KALA YTD return versus benchmarks:

YTD Return for S&P
YTD Return for Dow
YTD Return for Nasdaq 100
YTD Return for Russell 2000
YTD Return for Gold
YTD Return for 10 Year Treasury
YTD Return on $10,000.00
Without Dividends Reinvested Into KALA

Kala Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics using its AMPPLIFY™ Mucus Penetrating Particles drug delivery technology, with a focus on the treatment of eye diseases. Co.'s approved ocular corticosteroid product, INVELTYS™ (loteprednol etabonate ophthalmic suspension) is used for the treatment of post-operative inflammation and pain. Co. is developing KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. Co. is evaluating compounds in its receptor Tyrosine Kinase Inhibitor program that inhibit the vascular endothelial growth factor pathway for the treatment of a number of retinal diseases. The KALA YTD return is shown above.

The YTD Return on the KALA YTD return page and across the coverage universe of our site, is a measure of the total return for a given investment year-to-date for the current calendar year (up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely useful in the context of our country's tax system which taxes gains and income on a calendar year basis.

Thus, researching Year-To-Date Returns is good practice for investors — whether KALA YTD return or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the KALA YTD return calculation (with any dividends reinvested as applicable), and to provide a coverage universe of many stocks and ETFs to be able to compare YTD returns.
Quotes delayed 20 minutes
Get Free SEC filing alerts for KALA:
KALA SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in YTD Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Kala Pharmaceuticals (KALA) is categorized under the Healthcare sector; to help you further research YTD return performance across stocks, below are some other companies in the same sector:

KALV YTD Return
KBLM YTD Return
KDMN YTD Return
KEQU YTD Return
KERX YTD Return
KIDS YTD Return
KIN YTD Return
KMPH YTD Return
KND YTD Return
KOOL YTD Return
More Healthcare companies »

 

KALA YTD Return | www.YTDReturn.com | Copyright © 2017 - 2020, All Rights Reserved

Nothing in YTDReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.